Use of drotrecorgin alfa--recombinant activated human protein C in treatment of septic shock in the course of therapy for nephrolithiasis.
BACKGROUND
Septic shock is the most dangerous complication of nephrolithiasis management utilizing percutaneous methods.


METHODS
The patient, D.M., aged 60 was subjected to scheduled percutaneous nephrolithotomy due to coral calculosis of the pyelocalyceal system. As pyuria was noted intraoperatively, nephrostomy was left after the procedure. Over ten hours after the surgery the patient developed the symptoms of severe septic shock with progressive respiratory distress, renal failure, intravascular coagulation syndrome and impaired consciousness. Nephrectomy was performed, antibiotic treatment and high doses of norepinephrine instituted. Hemodynamic stabilization was obtained, without, however, marked improvement of the patient's condition. Because of persistent coagulation disorders and multiorgan dysfunction, recombinant activated protein C preparation--drotrecorgin alfa (Xigris Eli Lilly) was added to the therapeutic regimen. From the second day of infusion, systematic improvement of the coagulation system parameters was observed, making it possible to reduce the doses of catecholamines, oxygen concentration in the gas mixture used for ventilation, as well as stabilization of the function of the preserved kidney. The patient was weaned off the respirator on the 8th day of treatment and on the 13th day referred to the Urology Department, from which she was soon discharged home.


CONCLUSIONS
1. Surgical resection of the infection source and cause of the septic shock is the prerequisite for successful pharmacological treatment. 2. Administration of rh-APC to a patient meeting the PROWESS criteria may be an effective and safe method of treatment in the complex management of septic shock.
Biernacka
Jadwiga
J
Chair and 1st Department of Anesthesiology and Intensive Care, Medical University of Lublin, Poland. jbiernac2@wp.pl
Wośko
Jarosław
J
Dabrowski
Wojciech
W
Nestorowicz
Andrzej
A
D004211:Disseminated Intravascular Coagulation / Q000097:blood / Q000188:drug therapy / Q000209:etiology; D005260:Female; D006801:Humans; D007669:Kidney Calculi / Q000150:complications* / Q000628:therapy; D008875:Middle Aged; D009392:Nephrectomy; D009403:Nephrostomy, Percutaneous / Q000009:adverse effects; D011486:Protein C / Q000627:therapeutic use*; D011994:Recombinant Proteins / Q000627:therapeutic use*; D012772:Shock, Septic / Q000097:blood / Q000188:drug therapy* / Q000209:etiology*; D013203:Staphylococcal Infections / Q000097:blood / Q000188:drug therapy / Q000209:etiology; D041162:Staphylococcus haemolyticus
D011486:Protein C; D011994:Recombinant Proteins; C421124:drotrecogin alfa activated